Agilent Technologies, Inc. A
172.79
(0.05)
(0.03%)
as of 25 Sep
- Market cap
- $49.0B
- P/E
- 33.9×
Follow A
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Agilent Technologies, Inc. (A) Return on equity
Agilent Technologies, Inc.'s return on equity over the twelve months to 31 July 2026 was 21.0%, up 0.4 percentage points from fiscal 2025 (20.6%). Over the past ten years it has ranged from 6.72% (fiscal 2018) to 23.6% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Diagnostics & Research industry median of −2.92% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 20.6% | (1.33) |
| FY2024 | 22.0% | (0.29) |
| FY2023 | 22.2% | (1.21) |
| FY2022 | 23.5% | (0.13) |
| FY2021 | 23.6% | 8.63 |
| FY2020 | 15.0% | (8.04) |
| FY2019 | 23.0% | 16.27 |
| FY2018 | 6.72% | (8.34) |
| FY2017 | 15.1% | 4.08 |
| FY2016 | 11.0% | 2.51 |
Against its own ten years
Low 6.72%
High 23.6%
Ten-year median
20.6%
Current reading's percentile
55
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. compare | 171.6% |
| IDXX IDEXX Laboratories, Inc. compare | 74.2% |
| ILMN Illumina, Inc. compare | 32.4% |
| IQV IQVIA Holdings Inc. compare | 22.8% |
| A Agilent Technologies, Inc. | 21.0% |
| DGX Quest Diagnostics Incorporated compare | 14.0% |
| WAT Waters Corporation compare | 1.92% |
| NTRA Natera, Inc. compare | −12.5% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | −2.92% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on A
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement